Importantly, moving forward, the integration of DNA copy‐number alterations, methylome, mRNA and protein, metabolomics and clinical information may help to further delineate the extent of Src signalling deregulation in pancreatic and other cancers, and could potentially lay the foundation for more accurate and rapid implementation of therapeutic inhibitors of Src as personalised cancer therapeutics. The gene discussed is SRC; the disease is cancer.